Denmark's Novo Nordisk A/S, the world's biggest insulin producer, said on Friday its diabetes treatment Tresiba had been approved in Japan. Novo Nordisk said in a statement it expected to launch Tresiba in the country as soon as price negotiations have been completed, Reuters reported.